Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability (2022 - 2024)
Sunshine Biopharma's (SBFM) quarterly Non-Current Deferred Tax Liability came in at $141396.0 in Q4 2024, up 161.37% YoY from $54097.0 in Q1 2024, and up 190.17% on a QoQ basis from $48729.0 in Q3 2024.
Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability (2022 - 2024) Analysis & Trends
Sunshine Biopharma (SBFM) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $141396.0 in Q4 2024.
- Quarterly Non-Current Deferred Tax Liability rose 161.37% year-over-year to $141396.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $141396.0 (up 161.37% YoY) and the FY2024 annual result came in at $141396.0, up 161.37% from the prior year.
- Non-Current Deferred Tax Liability improved to $141396.0 in Q4 2024, from $48729.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $141396.0 in Q4 2024 to a low of $43032.0 in Q4 2022.
- A 3-year average of $57089.8 and a median of $48729.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The widest YoY moves for Non-Current Deferred Tax Liability: up 161.37% in 2024, down 13.24% in 2024.
- Tracing SBFM's Non-Current Deferred Tax Liability over 3 years: stood at $43032.0 in 2022, then advanced by 25.71% to $54097.0 in 2023, then surged by 161.37% to $141396.0 in 2024.
- The last three Non-Current Deferred Tax Liability figures came in at $141396.0 (Q4 2024), $48729.0 (Q3 2024), and $48729.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Sunshine Biopharma | 1.60 Mn | -12.15 Mn | 2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 141,396.00 |
| Dec 31, 2024 | 141,396.00 |
| Sep 30, 2024 | 48,729.00 |
| Sep 30, 2024 | 48,729.00 |
| Jun 30, 2024 | 48,729.00 |
| Jun 30, 2024 | 48,729.00 |
| Mar 31, 2024 | 48,729.00 |
| Mar 31, 2024 | 48,729.00 |
| Dec 31, 2023 | 54,097.00 |
| Dec 31, 2023 | 54,097.00 |
| Sep 30, 2023 | 43,032.00 |
| Sep 30, 2023 | 43,032.00 |
| Jun 30, 2023 | 43,032.00 |
| Jun 30, 2023 | 43,032.00 |
| Mar 31, 2023 | 43,032.00 |
| Mar 31, 2023 | 43,032.00 |
| Dec 31, 2022 | 43,032.00 |
| Dec 31, 2022 | 43,032.00 |